Relmacabtagene Autoleucel in Hematologic Malignancies
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorShanghai Ming Ju Biotechnology Co., Ltd.
About this trial
To evaluate the efficacy and safety of Relmacabtagene Autoleucel in the treatment of adult patients with hematologic malignancies in real-world
Eligibility criteria
Qualifiers
Signed informed consent
Patients who have been treated with Relma-cel, including those who have received off-label products;
If previously enrolled in another clinical study, they must have completed follow-up in the previous study, or have withdrawn or lost follow-up in the previous study.
Disqualifiers
None
Trial design
Treatments tested in this trial
- Relmacabtagene Autoleucel
Treatment groups
150 Participants
are divided into 1 treatment groupLocations
2Beijing Cancer Hospital100010, BeijingBeijing Municipality, China
Peking University International Hospital100010, BeijingBeijing Municipality, China
Sponsors and collaborators
Shanghai Ming Ju Biotechnology Co., Ltd.
Lead sponsor
Source ClinicalTrials.gov